2020 Fiscal Year Final Research Report
miRNA functional analysis in BET inhibitors
| Project/Area Number |
18K08131
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53030:Respiratory medicine-related
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Keywords | BET阻害剤 |
|---|
| Outline of Final Research Achievements |
BET inhibitors are beginning to be applied as new therapeutic agents for cancer. The function of BET inhibitors on BET family proteins has been well studied, but the mechanism of action of cancer treatment remains unclear. Our primary research revealed that long-term administration of BET inhibitors causes cancer cells to acquire resistance to BET inhibitors. Furthermore, we performed a genetic analysis of the BRD genes, but the gene mutations were unclear. As a result of analyzing miRNA, it was found that a miRNA expression was elevated in the resistant cells.
|
| Free Research Field |
呼吸器内科
|
| Academic Significance and Societal Importance of the Research Achievements |
我々の研究結果から、がん細胞はBET阻害剤に耐性を獲得してしまうことがわかった。さらに、その機序としてはブロモドメイン領域の獲得耐性変異ではないことも突き止めた。一部で癌の増殖を亢進するようなOncomiRNAの発現が上昇していたことから、BET阻害剤耐性の1つの機序として考えられた。これらの成果から、BET阻害剤の臨床応用の際には獲得耐性の克服が重要であることが示唆された。
|
